Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is a treatment that engineers the patient’s own immune system to more effectively fight cancer.
Certain immune system cells, called T-cells, can normally identify cancer cells and destroy them before they multiply and cause disease. Sometimes, however, T-cells have trouble detecting cancer cells.
CAR T-cell therapy removes T-cells from the blood and inserts a new gene into them to make it easier for the T-cells to fight cancer. The new cells are called CAR T-cells.
The CAR T-cells are then infused into the patient to begin fighting cancer.
Diseases Treated by CAR-T
As of November 2024, the U.S. Food and Drug Administration (FDA) has approved the following CAR T-cell therapies for patients who relapsed or did not respond to treatment after several rounds of therapy:
- Abecma® (idecabtagene vicleucel; ide-cel) for adults with multiple myeloma
- Aucatzyl® (obecabtagene autoleucel; obe-cel) for adults with B-cell acute lymphoblastic leukemia.
- Breyanzi® (lisocabtagene maraleucel; liso-cel) for adults with::
- large B-cell lymphoma
- follicular lymphoma
- mantle cell lymphoma
- chronic lymphocytic leukemia
- small lymphocytic lymphoma
- Carvykti™ (ciltacabtagene autoleucel) for adults with multiple myeloma
- Kymriah® (tisagenlecleucel) for:
- children and young adults up to 25 years old with B-cell acute lymphoblastic leukemia
- adults with large B-cell lymphoma or follicular lymphoma
- Tecartus® (brexucabtagene autoleucel; brexu-cel) for adults with:
- mantle cell lymphoma
- B-cell acute lymphoblastic leukemia (ALL)
- Yescarta® (axicabtagene ciloleucel; axi-cel)) for adults with:
- large B-cell lymphomas
- follicular lymphoma
The specific CAR T-therapy available to you will vary depending on the medical center where you are receiving treatment and the characteristics of your disease.
In addition to FDA-approved CAR T-cell therapies, your treatment center may offer you the opportunity to participate in a clinical trial testing a new type.of CAR T-cell therapy.
Research is underway to determine if patients with other types of cancer, such as acute myeloid leukemia (AML), Hodgkin lymphoma, some autoimmune diseases, and some solid tumors can also benefit from CAR T-cell therapy.
Watch this video about CAR T-cell therapy for patients with multiple myeloma. Click here to read the transcript and download the slides.
\Watch this video about CAR T-cell therapy for patients with acute lymphoblastic leukemia (ALL). Click here to read the transcript and download the slides.
NEXT: Steps Involved in CAR T-cell Therapy
Updated November 2024
